#United States #NASDAQ #Menlo Park #RSUs #GRAIL

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

On August 29, 2025, GRAIL, Inc., a prominent healthcare company dedicated to the early detection of cancer, disclosed its recent issuance of equity awards to newly hired employees. This strategic move aims to attract talent by offering restricted stock units (RSUs) linked to an aggregate of 47,150 shares of the company's common stock. The awards are specifically intended for 27 recently recruited non-executive staff members, serving as an inducement crucial for their acceptance of employment at GRAIL.

The equity grants fall under GRAIL's Inducement Equity Incentive Plan and adhere to the guidelines established by NASDAQ Listing Rule 5635(c)(4). This rule allows companies to offer equity awards as an incentive to individuals who have not been prior employees or have had a significant period of non-employment.

The awarded RSUs are designed to vest over a four-year timeline. The initial 25% of the grant is set to vest on August 31, 2026, with the remainder vesting annually thereafter, contingent upon the recipients maintaining their employment with GRAIL or its affiliated entities during the vesting timeline.

The Vision Behind GRAIL

GRAIL's core mission revolves around the early detection of cancer, a critical factor in effective treatment and potential cure. The organization leverages state-of-the-art technology, including next-generation sequencing, comprehensive population-scale clinical studies, and advanced machine learning methodologies. These tools enable the company to identify and detect several types of cancer in their earlier stages when treatment is most likely to succeed.

GRAIL’s innovative methylation-based platform is pivotal in supporting a comprehensive approach to healthcare that encompasses multi-cancer early detection. This approach also facilitates risk stratification, minimal residual disease detection, biomarker subtyping, and ongoing monitoring for treatment efficacy and recurrence.

Headquartered in Menlo Park, California, GRAIL has extended its operations beyond U.S. borders, establishing locations in Washington, D.C., North Carolina, and the United Kingdom. The company's commitment is directed towards alleviating the global burden of cancer through ground-breaking technologies that enhance the continuum of care.

As GRAIL forges ahead with its mission, the recent inducement grants underscore the company’s strength in attracting top talent essential for driving innovation in cancer detection. With these efforts, GRAIL is not only investing in its workforce but also reinforcing its dedication to transforming healthcare.

For more information on GRAIL and its groundbreaking initiatives, visit grail.com.